Key Highlights

  • Chimeric Therapeutics (ASX:CHM) shares rose over 13% to $0.043 on 29 July 2026 following the funding announcement.
  • The company received $1.62 million from Endpoints Capital, secured against its anticipated FY26 R&D Tax Incentive.
  • The funds will support ongoing Phase 1/2 clinical trial activities and general working capital during the company's Strategic Review.
  • A separate R&D facility with Radium Capital, announced in March 2026, has now been fully repaid and discharged.

Chimeric Therapeutics Ltd (ASX:CHM) shares advanced on 29 July 2026, rising more than 13% to trade at $0.043, with the move coming shortly after midday following the release of the company's funding update. The gain reflects investor interest in news that provides the cell therapy company with additional near-term liquidity while it continues to progress its clinical programs and a previously flagged Strategic Review.

For a company operating in the clinical-stage biotechnology segment, funding announcements of this nature are often closely watched by the market given the ongoing capital requirements associated with running clinical trials. The share price reaction on the day suggests the market viewed the facility as a constructive development in the context of the company's broader funding position.

Details of the R&D Tax Incentive Funding Facility

The Sydney-based company confirmed it has received $1,620,000 from Endpoints Capital under a funding facility secured against Chimeric's anticipated FY26 Research and Development Tax Incentive, commonly referred to as the RDTI. The Australian Government's RDTI program provides eligible companies undertaking qualifying research and development activities with a refundable tax offset of up to 43.5%, and facilities of this type allow companies to access a portion of that anticipated benefit ahead of its formal receipt from the Australian Taxation Office.

Under the terms disclosed, the facility is secured against the company's anticipated FY26 RDTI entitlement, with interest charged at a commercial rate. Repayment is timed to follow the expected receipt of the RDTI amount from the Australian Taxation Office and is due by 31 December 2026, although the company retains the ability to repay the facility earlier, subject to its terms.

Use of Funds and Strategic Review Context

Chimeric said the funding received will support its ongoing Phase 1/2 clinical trial activities as well as general working capital requirements. The company noted it is currently undertaking a previously announced Strategic Review, and stated that the ability to access funding to support related initiatives is a key requirement during this period. The disclosure links the new facility directly to the company's capacity to maintain trial momentum while that review is underway.

Repayment of Prior Facility

In the same announcement, Chimeric confirmed that the principal and interest owing under a separate R&D funding facility with Radium Capital, which had been announced on 2 March 2026, has now been fully repaid and discharged. The clearing of this earlier facility, alongside the establishment of the new Endpoints Capital arrangement, points to an active management of the company's funding structure as it works through the current stage of clinical development and corporate review.

Company Background

Chimeric Therapeutics describes itself as a cell therapy company focused on the development of novel treatments, with clinical programs progressing through Phase 1/2 stages. As is common among clinical-stage biotechnology companies listed on the ASX, Chimeric has periodically sought funding through a combination of equity raisings and specialised facilities linked to government incentive programs such as the RDTI, reflecting the capital-intensive nature of advancing cell therapy candidates through clinical trials.

Broader Funding Landscape for Clinical-Stage Biotechs

RDTI-linked funding facilities of the type used by Chimeric have become an established mechanism among ASX-listed clinical-stage companies seeking to bridge the gap between incurring eligible research and development expenditure and the subsequent receipt of the government tax offset. Because the RDTI is paid in arrears following the relevant financial year, companies that would otherwise have to wait for the payment can instead access a portion of the anticipated benefit earlier, at the cost of the commercial interest rate charged on the facility. For companies managing multiple concurrent clinical trial sites, this type of facility can supplement equity funding rounds without immediately diluting existing shareholders.

The disclosure that the company's prior Radium Capital facility has been fully discharged, alongside the establishment of the new Endpoints Capital arrangement, indicates that Chimeric has been actively managing the sequencing of its RDTI-linked funding across financial years, rolling from one facility into the next as new R&D expenditure and corresponding tax offset entitlements accrue.

Conclusion

The $1.62 million funding advance from Endpoints Capital provides Chimeric Therapeutics with additional working capital as it continues its Phase 1/2 clinical trial program and progresses its Strategic Review, while the discharge of the earlier Radium Capital facility simplifies the company's funding arrangements. The share price response on the day of the announcement indicates the market registered the update as a relevant development in the company's ongoing funding position, with further clarity likely to emerge as the Strategic Review process continues.